aTyr Pharma Announces Research Study with Stanford Medicine
aTyr Pharma (Nasdaq: ATYR) has entered a research agreement with Stanford Medicine to explore the role of anti-NRP2 antibodies in glioblastoma multiforme (GBM), the most common primary brain cancer. The study, led by Dr. Michael Lim, aims to investigate the potential of aTyr's novel function blocking antibodies against NRP2 in combination with chemotherapy to reverse immune evasion in GBM. If successful, researchers plan to evaluate NRP2 antibodies with other immunomodulating agents to address myeloid and T cell immunosuppression in GBM treatment.
This collaboration aligns with aTyr's belief that NRP2 plays a important role in immune cross talk in various cancers. The research could enhance understanding of NRP2's role in mediating immune suppression in aggressive cancers like GBM, where there is a high unmet medical need. GBM's current standard of care includes surgery, radiation, and chemotherapy, but the rate of recurrence remains high, emphasizing the need for new treatments to manage recurrence.
aTyr Pharma (Nasdaq: ATYR) ha stipulato un accordo di ricerca con la Stanford Medicine per esplorare il ruolo degli anticorpi anti-NRP2 nel glioblastoma multiforme (GBM), il cancro cerebrale primario più comune. Lo studio, guidato dal Dr. Michael Lim, mira a investigare il potenziale dei nuovi anticorpi bloccanti di funzione di aTyr contro NRP2 in combinazione con la chemioterapia per invertire l'evasione immunitaria nel GBM. Se avrà successo, i ricercatori prevedono di valutare gli anticorpi NRP2 insieme ad altri agenti immunomodulanti per affrontare l'immunosoppressione dei linfociti mieloidi e T nel trattamento del GBM.
Questa collaborazione si allinea con la convinzione di aTyr che NRP2 svolga un ruolo importante nella comunicazione immunitaria in vari tipi di cancro. La ricerca potrebbe migliorare la comprensione del ruolo di NRP2 nella mediazione dell'immunosoppressione in tumori aggressivi come il GBM, dove esiste un grande bisogno medico non soddisfatto. L'attuale standard di cura per il GBM comprende chirurgia, radioterapia e chemioterapia, ma il tasso di recidiva rimane elevato, sottolineando la necessità di nuovi trattamenti per gestire le recidive.
aTyr Pharma (Nasdaq: ATYR) ha firmado un acuerdo de investigación con Stanford Medicine para explorar el papel de los anticuerpos anti-NRP2 en el glioblastoma multiforme (GBM), el cáncer cerebral primario más común. El estudio, liderado por el Dr. Michael Lim, tiene como objetivo investigar el potencial de los nuevos anticuerpos bloqueadores de función de aTyr contra NRP2 en combinación con la quimioterapia para revertir la evasión inmune en el GBM. Si tiene éxito, los investigadores planean evaluar los anticuerpos NRP2 con otros agentes inmunomoduladores para abordar la inmunosupresión de células mieloides y T en el tratamiento del GBM.
Esta colaboración está en línea con la creencia de aTyr de que NRP2 desempeña un papel importante en la comunicación inmune en varios tipos de cáncer. La investigación podría mejorar la comprensión del papel de NRP2 en la mediación de la inmunosupresión en cánceres agresivos como el GBM, donde existe una gran necesidad médica no satisfecha. El estándar de atención actual para el GBM incluye cirugía, radioterapia y quimioterapia, pero la tasa de recurrencia sigue siendo alta, lo que enfatiza la necesidad de nuevos tratamientos para manejar la recurrencia.
aTyr Pharma(Nasdaq: ATYR)는 스탠포드 의학과 연구 계약을 체결하고 다형성 교모세포종(GBM)에서 항-NRP2 항체의 역할을 탐구합니다. 이 연구는 Michael Lim 박사가 이끌며, aTyr의 새로운 기능 차단 항체가 NRP2에 대해 화학요법과 함께 면역 회피를 역전시키는 가능성을 조사하는 것을 목표로 합니다. 성공할 경우, 연구자들은 GBM 치료에서 골수 및 T 세포 면역 억제를 해결하기 위해 다른 면역 조절제와 함께 NRP2 항체를 평가할 계획입니다.
이 협력은 다양한 암에서 NRP2가 면역 대화에서 중요한 역할을 한다고 믿는 aTyr의 신념과 일치합니다. 이 연구는 GBM과 같은 공격적인 암에서 면역 억제를 매개하는 NRP2의 역할에 대한 이해를 높일 수 있습니다. GBM의 현재 표준 치료는 수술, 방사선 치료 및 화학 요법을 포함하지만, 재발률이 여전히 높아 재발 관리를 위한 새로운 치료의 필요성이 강조됩니다.
aTyr Pharma (Nasdaq: ATYR) a signé un accord de recherche avec Stanford Medicine pour explorer le rôle des anticorps anti-NRP2 dans le glioblastome multiforme (GBM), le cancer cérébral primaire le plus courant. L'étude, dirigée par le Dr Michael Lim, vise à examiner le potentiel des nouveaux anticorps bloquants de fonction d'aTyr contre NRP2 en combinaison avec une chimiothérapie pour inverser l'évasion immunitaire dans le GBM. En cas de succès, les chercheurs prévoient d'évaluer les anticorps NRP2 avec d'autres agents immunomodulateurs pour traiter l'immunosuppression des cellules myéloïdes et T dans le traitement du GBM.
Cette collaboration est en accord avec la conviction d'aTyr que NRP2 joue un rôle important dans la communication immunitaire dans divers types de cancers. La recherche pourrait améliorer la compréhension du rôle de NRP2 dans la médiation de l'immunosuppression dans des cancers agressifs comme le GBM, où il existe un grand besoin médical non satisfait. Le standard actuel de soins pour le GBM comprend la chirurgie, la radiothérapie et la chimiothérapie, mais le taux de récidive reste élevé, soulignant la nécessité de nouveaux traitements pour gérer les récidives.
aTyr Pharma (Nasdaq: ATYR) hat eine Forschungsvereinbarung mit der Stanford Medicine geschlossen, um die Rolle von Anti-NRP2-Antikörpern im glioblastoma multiforme (GBM), dem häufigsten primären Gehirntumor, zu untersuchen. Die Studie, die von Dr. Michael Lim geleitet wird, zielt darauf ab, das Potenzial von aTyrs neuartigen funktionsblockierenden Antikörpern gegen NRP2 in Kombination mit Chemotherapie zu untersuchen, um die Immunflucht im GBM umzukehren. Bei Erfolg planen die Forscher, NRP2-Antikörper zusammen mit anderen immunmodulierenden Agenzien zu bewerten, um die myeloische und T-Zell-Immunosuppression in der GBM-Behandlung anzugehen.
Diese Zusammenarbeit entspricht aTyrs Überzeugung, dass NRP2 eine wichtige Rolle im immunologischen Austausch in verschiedenen Krebsarten spielt. Die Forschung könnte das Verständnis der Rolle von NRP2 bei der Mediation der Immununterdrückung in aggressiven Krebsarten wie GBM verbessern, wo ein hoher unerfüllter medizinischer Bedarf besteht. Der aktuelle Standard der Behandlung für GBM umfasst Chirurgie, Strahlentherapie und Chemotherapie, doch die Rückfallrate bleibt hoch, was die Notwendigkeit neuer Behandlungen zur Bewältigung von Rückfällen unterstreicht.
- Research collaboration with Stanford Medicine to explore anti-NRP2 antibodies in GBM treatment
- Potential to address immune evasion in aggressive brain cancer with high unmet medical need
- Opportunity to enhance mechanistic understanding of NRP2's role in immune suppression
- None.
This research collaboration between aTyr Pharma and Stanford Medicine marks a significant step in exploring novel approaches to treat glioblastoma multiforme (GBM), a highly aggressive form of brain cancer. The study's focus on anti-NRP2 antibodies in combination with other therapies could potentially open new avenues for managing this difficult-to-treat condition.
Key points to consider:
- The collaboration aims to investigate the role of aTyr's anti-NRP2 antibodies in reversing immune evasion in GBM, particularly when combined with chemotherapy.
- If successful, the research may lead to further studies combining these antibodies with other immunomodulating agents, targeting multiple aspects of immune suppression in GBM.
- The involvement of Dr. Michael Lim, a renowned expert in brain tumor immunotherapy, lends credibility to this research endeavor.
While this news is promising, it's important to note that this is an early-stage research collaboration. The path from preclinical research to approved therapies is long and often fraught with challenges. Investors should view this as a long-term potential rather than an immediate value driver for aTyr Pharma.
The unmet medical need in GBM is significant, with current treatments offering efficacy and high recurrence rates. If aTyr's approach proves successful, it could represent a major advancement in GBM treatment, potentially leading to improved patient outcomes and a substantial market opportunity.
However, it's important to remember that many promising preclinical studies fail to translate into effective treatments. Investors should monitor future updates on this collaboration, particularly any data that emerges from the preliminary studies.
The collaboration between aTyr Pharma and Stanford Medicine to explore anti-NRP2 antibodies in glioblastoma multiforme (GBM) treatment is an intriguing development in the field of neuro-oncology. Here's why this research is significant:
- GBM is notoriously difficult to treat, with a median survival of only 12-15 months with current standard therapies. Any new approach that could potentially improve outcomes is worth investigating.
- The focus on reversing immune evasion in GBM aligns with the growing understanding of the important role the immune system plays in cancer progression and treatment.
- Combining anti-NRP2 antibodies with existing therapies like chemotherapy and potentially other immunomodulating agents represents a multi-pronged approach to tackling GBM's complex biology.
The involvement of Dr. Michael Lim, an expert in GBM immunosuppression, adds weight to this research. His expertise in stimulating myeloid cells to reverse immunosuppression in the tumor microenvironment could be important in understanding how anti-NRP2 antibodies might fit into the treatment landscape.
However, it's important to temper expectations. Many promising preclinical studies in GBM have failed to translate into clinical benefits. The complexity of the brain tumor microenvironment and the blood-brain barrier present significant challenges for drug delivery and efficacy.
If successful, this research could lead to a new paradigm in GBM treatment, potentially improving survival rates and quality of life for patients. However, investors should be aware that the road from preclinical research to approved therapy is long and uncertain, especially in the challenging field of brain cancer treatment.
Study to explore role of the Company’s anti-NRP2 antibodies in glioblastoma multiforme (GBM), the most common type of primary brain cancer.
SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it has entered into a research agreement with Stanford Medicine. Michael Lim, M.D., Chair of the Department of Neurosurgery at Stanford Medicine, will serve as the principal investigator for the study. Dr. Lim’s research focuses on understanding the basic mechanisms of immunosuppression in glioblastoma multiforme (GBM).
“We know that the immune system plays an important role in GBM recurrence, and we have studied stimulating myeloid cells as a way to reverse immunosuppression in the tumor microenvironment,” said Dr. Lim. “We look forward to looking at the role in which anti-neuropilin-2 (NRP2) antibodies in combination with other therapies may play in reactivating the immune system in order to reduce tumor recurrence.”
The research collaboration aims to explore the role of the Company’s novel function blocking antibodies against NRP2 in combination with chemotherapy to evaluate their role in reversing immune evasion in GBM. If preliminary studies are successful, the researchers plan to evaluate the NRP2 antibodies in combination with other immunomodulating agents, such as anti-PD-1, STING, or anti-CSF-1R, to address multiple targets of myeloid and T cell immunosuppression for the potential treatment of GBM.
“We are pleased to initiate this research collaboration with Stanford Medicine and Dr. Lim, a leader in immunotherapy for brain tumors, to explore the potential for combination therapy with NRP2-targeted antibodies in GBM,” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. “While we are focused on advancing our tRNA synthetase derived therapies, we believe NRP2 may play an important yet largely underappreciated role in immune cross talk in many cancers, including GBM. This study presents an important opportunity to enhance our mechanistic understanding regarding the role of NRP2 in mediating immune suppression in an extremely aggressive cancer where there is a high unmet medical need.”
GBM is a fast-growing and aggressive brain tumor that invades the nearby brain tissue but does not typically spread to other organs. GBM can result in death in less than 6 months. Current standard of care includes surgery followed by radiation and chemotherapy, which can extend survival but is not curative and the rate of recurrence is high. Research that explores the underlying causes and mechanism of recurrence may lead to new treatments that can address and help manage recurrence, which are greatly needed.
About aTyr
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are usually identified by the use of words such as “aim,” “anticipate,” “believes,” “designed,” “can,” “expects,” “intends,” “may,” “opportunity,” “plans,” “potential,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by such safe harbor provisions for forward-looking statements and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements include, among others, statements regarding the potential therapeutic benefits and applications of NRP2 antibodies; timelines, plans and expected results with respect to certain research and development activities and the expected personnel involved in such activities; potential benefits of collaborations; and certain development goals. These forward-looking statements also reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects, as reflected in or suggested by these forward-looking statements, are reasonable, we can give no assurance that the plans, intentions, expectations, strategies or prospects will be attained or achieved. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. Furthermore, actual results may differ materially from those described in these forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, uncertainty regarding geopolitical and macroeconomic events, risks associated with the discovery, development and regulation of our product candidates, the risks inherent in studies of potential medical therapies, the risk that we or our partners may cease or delay preclinical or clinical development activities for any of our existing or future product candidates for a variety of reasons (including difficulties or delays in patient enrollment in planned clinical trials), the possibility that existing collaborations could be terminated early, and the risk that we may not be able to raise the additional funding required for our business and product development plans, as well as those risks set forth in our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and in our other SEC filings. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Ashlee Dunston
Director, Investor Relations and Public Affairs
adunston@atyrpharma.com
FAQ
What is the focus of aTyr Pharma's research study with Stanford Medicine?
Who is the principal investigator for the aTyr Pharma and Stanford Medicine GBM study?
What is the potential benefit of combining aTyr's NRP2 antibodies with other therapies for GBM?
Why is new research important for glioblastoma multiforme (GBM) treatment?
